Analysts predict that Kezar Life Sciences Inc (NASDAQ:KZR) will post ($0.48) earnings per share (EPS) for the current quarter, Zacks reports. Zero analysts have made estimates for Kezar Life Sciences’ earnings, with the lowest EPS estimate coming in at ($0.62) and the highest estimate coming in at ($0.40). The company is scheduled to issue its next quarterly earnings results on Thursday, November 8th.

According to Zacks, analysts expect that Kezar Life Sciences will report full-year earnings of ($2.64) per share for the current financial year, with EPS estimates ranging from ($3.11) to ($2.10). For the next fiscal year, analysts forecast that the business will report earnings of ($2.26) per share, with EPS estimates ranging from ($2.84) to ($1.75). Zacks’ EPS averages are an average based on a survey of sell-side analysts that cover Kezar Life Sciences.

Kezar Life Sciences (NASDAQ:KZR) last announced its earnings results on Thursday, August 9th. The company reported ($3.31) EPS for the quarter, missing analysts’ consensus estimates of ($0.54) by ($2.77).

A number of brokerages have commented on KZR. Wells Fargo & Co began coverage on Kezar Life Sciences in a report on Monday, July 16th. They set an “outperform” rating and a $30.00 target price for the company. Jefferies Financial Group began coverage on Kezar Life Sciences in a report on Monday, July 16th. They set a “buy” rating and a $23.00 target price for the company. Cowen began coverage on Kezar Life Sciences in a report on Monday, July 16th. They set an “outperform” rating for the company. Finally, William Blair began coverage on Kezar Life Sciences in a report on Monday, July 16th. They set an “outperform” rating for the company.

Institutional investors have recently made changes to their positions in the business. FMR LLC acquired a new stake in shares of Kezar Life Sciences in the second quarter valued at approximately $25,995,000. Cowen Inc. acquired a new stake in shares of Kezar Life Sciences in the second quarter valued at approximately $18,207,000. Frazier Management LLC acquired a new stake in shares of Kezar Life Sciences in the second quarter valued at approximately $4,325,000. Acuta Capital Partners LLC acquired a new stake in shares of Kezar Life Sciences in the second quarter valued at approximately $1,730,000. Finally, Millennium Management LLC acquired a new stake in shares of Kezar Life Sciences in the second quarter valued at approximately $1,300,000. 42.18% of the stock is owned by institutional investors and hedge funds.

Shares of Kezar Life Sciences stock opened at $20.41 on Friday. Kezar Life Sciences has a 12 month low of $14.77 and a 12 month high of $21.34.

About Kezar Life Sciences

Kezar Life Sciences, Inc, a clinical-stage biotechnology company, engages in the discovery and development of small molecule therapeutics to treat unmet needs in autoimmunity and cancer in the United States. Its lead product candidate, KZR-616, a selective immunoproteasome inhibitor that is in Phase 1b/2 clinical trials in lupus and lupus nephritis The company was incorporated in 2015 and is headquartered in South San Francisco, California.

Featured Article: S&P 500 Index

Get a free copy of the Zacks research report on Kezar Life Sciences (KZR)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Kezar Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kezar Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.